Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical anticachexia treatments.

Michael J Tisdale1

  • 1Molecular Biosciences, School of Life and Health Sciences, Aston University, Birmingham B4 7ET, United Kingdom. m.j.tisdale@aston.ac.uk

Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition
|March 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Simple ammonium salts acting on sigma-1 receptors yield potential treatments for cancer and depression.

Scientific reports·2020
Same author

Ken Fearon.

Cell metabolism·2016
Same author

In vitro assessment of the combined effect of eicosapentaenoic acid, green tea extract and curcumin C3 on protein loss in C2C12 myotubes.

In vitro cellular & developmental biology. Animal·2016
Same author

Comparison of the anticatabolic effects of leucine and Ca-β-hydroxy-β-methylbutyrate in experimental models of cancer cachexia.

Nutrition (Burbank, Los Angeles County, Calif.)·2014
Same author

Attenuation of muscle wasting in murine C2C 12 myotubes by epigallocatechin-3-gallate.

Journal of cachexia, sarcopenia and muscle·2014
Same author

Role of β-adrenergic receptors in the oral activity of zinc-α2-glycoprotein (ZAG).

Endocrinology·2012

Cachexia treatment shows promise with agents blocking protein breakdown and stimulating synthesis. Further research into muscle protein mechanisms is needed for new therapies.

Area of Science:

  • Biomedical Science
  • Clinical Pharmacology
  • Oncology

Background:

  • Cachexia is a severe condition characterized by progressive loss of muscle and adipose tissue.
  • It is prevalent in end-stage diseases, leading to weakness, immobility, and reduced quality of life.
  • Current treatments aim to manage symptoms and improve patient outcomes.

Purpose of the Study:

  • To review agents clinically evaluated for cachexia treatment.
  • To discuss their mechanisms of action and effectiveness.
  • To identify areas for future research in cachexia therapeutics.

Main Methods:

  • Comprehensive review of the medical literature.
  • Focus on agents that have undergone clinical evaluation for cachexia.
  • Analysis of drug mechanisms, including protein synthesis and degradation pathways.

Related Experiment Videos

Main Results:

  • Megestrol acetate, corticosteroids, eicosapentaenoic acid, and thalidomide have demonstrated success.
  • Agents targeting the ubiquitin-proteasome pathway show efficacy by blocking protein degradation.
  • Combining protein degradation blockers with protein synthesis stimulators may increase muscle mass.
  • Appetite stimulants like cannabinoids were ineffective in preventing weight loss.

Conclusions:

  • Several agents show promise in managing cachexia, particularly those affecting protein metabolism.
  • Blocking protein degradation and stimulating protein synthesis are key therapeutic strategies.
  • Further fundamental research into skeletal muscle protein synthesis and degradation is crucial for developing novel treatments.